Annovis Partners With Neurorpm To Deploy AI-Powered Digital Biomarker Technology In Parkinson's Disease Study
(MENAFN - GlobeNewsWire - Nasdaq) MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (–Annovis– or the–Company–), a Phase 3 clinical-stage biotechnology company ...
Menafn
via Menafn - Corroborated by 1 others
Updated 2h ago
Source Verification
Corroboration Score: 2This story was independently reported by 2 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
A Combination of Techniques Leads to Improved Friction Stir Welding
Next
Global Data Center Infrastructure Management Market to Reach USD 11 Billion by 2032, Says MarkNtel Advisors
Related Articles
BusinessFayetteville partners with aviation school for program at Drake Field that leaders say will bring jobs to city
Nwa Democrat-47m ago-1 sources
BusinessDemi Lovato Finally Addresses Why She Sang ‘Heart Attack’ at an American Heart Association Event
Hannah Dailey-52m ago-1 sources
Business‘Uncanny Valley’: Nvidia’s ‘Super Bowl of AI,’ Tesla Disappoints, and Meta’s VR Metaverse ‘Shutdown’
Brian Barrett,Zoë Schiffer-53m ago-1 sources